Literature DB >> 21778120

Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease.

Martijn A Spruit1, Michael I Polkey, Bartolome Celli, Lisa D Edwards, Michael L Watkins, Victor Pinto-Plata, Jørgen Vestbo, Peter M A Calverley, Ruth Tal-Singer, Alvar Agusti, Harvey O Coxson, David A Lomas, William MacNee, Stephen Rennard, Edwin K Silverman, Courtney C Crim, Julie Yates, Emiel F M Wouters.   

Abstract

BACKGROUND: Exercise tolerance is an important clinical aspect of chronic obstructive pulmonary disease that can be easily and reliably measured with the 6-minute walking test (6MWT). To improve the utility of the 6MWT for patient and health care system management, the interpretation of the functional status measure in relation to death and hospitalization should be elucidated.
METHODS: Three-year, prospective, multicenter observational study to evaluate the predictive power of 6MWD for death or exacerbation-related hospitalization and to evaluate the factors that help determine 6MWD.
RESULTS: We measured 6MWD at baseline and annually in 2110 patients with clinically stable Global Initiative for Obstructive Lung Disease (GOLD) stage II-IV COPD and recorded exacerbation-related hospitalizations and all-cause mortality. During the study, 200 patients died and 650 were hospitalized. Using receiver operating characteristics, the best predictive thresholds of the 6MWD were 334 m for increased risk of death and 357 m for exacerbation-related hospitalization (area under the curve 0.67 and 0.60 respectively); however, the discriminatory thresholds, especially for mortality, were influenced by age. The mean (SE) 6MWD declined by 1.6 (1.2) m per year in GOLD II, 9.8 (1.3) m per year in GOLD III, and 8.5 (2.4) m per year in GOLD IV.
CONCLUSION: The 6MWD provides prognostic information that may be useful for identifying high-risk patients with COPD. Copyright Â
© 2012 American Medical Directors Association, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21778120     DOI: 10.1016/j.jamda.2011.06.009

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  71 in total

Review 1.  Updates in Chronic Obstructive Pulmonary Disease for the Year 2014.

Authors:  Sibel Atış Naycı; Lütfi Çöplü; Alev Gürgün; Nurdan Köktürk; Mehmet Polatlı; Elif Şen; Sema Umut; Esra Uzaslan; Nurhayat Yıldırım; Peter J Barnes
Journal:  Turk Thorac J       Date:  2015-04-01

2.  EECP improves markers of functional capacity regardless of underlying ranolazine therapy.

Authors:  Sanaz Ziad; Jamil Malik; Obinna Isiguzo; Lang Xu; Leqi Chen; Annette Cox; Sachin A Shah
Journal:  Am J Cardiovasc Dis       Date:  2020-12-15

3.  Six-minute-walk distance and accelerometry predict outcomes in chronic obstructive pulmonary disease independent of Global Initiative for Chronic Obstructive Lung Disease 2011 Group.

Authors:  Michael T Durheim; Patrick J Smith; Michael A Babyak; Stephanie K Mabe; Tereza Martinu; Karen E Welty-Wolf; Charles F Emery; Scott M Palmer; James A Blumenthal
Journal:  Ann Am Thorac Soc       Date:  2015-03

Review 4.  Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy.

Authors:  Thomas W Storer; Renee Miciek; Thomas G Travison
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

5.  Determinants of gait speed in COPD.

Authors:  Craig Karpman; Zachary S DePew; Nathan K LeBrasseur; Paul J Novotny; Roberto P Benzo
Journal:  Chest       Date:  2014-07       Impact factor: 9.410

6.  Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial.

Authors:  Michael I Polkey; Jens Praestgaard; Amy Berwick; Frits M E Franssen; Dave Singh; Michael C Steiner; Richard Casaburi; Hanns-Christian Tillmann; Estelle Lach-Trifilieff; Ronenn Roubenoff; Daniel S Rooks
Journal:  Am J Respir Crit Care Med       Date:  2019-02-01       Impact factor: 21.405

7.  Performance difference on the six-minute walk test on tracks of 20 and 30 meters for patients with chronic obstructive pulmonary disease: validity and reliability.

Authors:  Suelen Roberta Klein; Aline Almeida Gulart; Raysa Silva Venâncio; Anelise Bauer Munari; Simone Graciosa Gavenda; Ana Carolina Benedet Martins; Anamaria Fleig Mayer
Journal:  Braz J Phys Ther       Date:  2020-01-22       Impact factor: 3.377

8.  The 2014 Updated GOLD Strategy: A Comparison of the Various Scenarios.

Authors:  Sarah Wilke; Dionne E Smid; Martijn A Spruit; Daisy J A Janssen; Jean W M Muris; Thys van der Molen; Marjan van den Akker; Paul W Jones; Emiel F M Wouters; Frits M E Franssen
Journal:  Chronic Obstr Pulm Dis       Date:  2014-09-25

Review 9.  Systematic Review of the Association Between Laboratory- and Field-Based Exercise Tests and Lung Function in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Martin Bell; Iain Fotheringham; Yogesh Suresh Punekar; John H Riley; Sarah Cockle; Sally J Singh
Journal:  Chronic Obstr Pulm Dis       Date:  2015-07-08

10.  Six minute walk distance is a predictor of survival in patients with chronic obstructive pulmonary disease undergoing pulmonary rehabilitation.

Authors:  Esther Dajczman; Rima Wardini; Goulnar Kasymjanova; David Préfontaine; Marc Alexander Baltzan; Norman Wolkove
Journal:  Can Respir J       Date:  2015 Jul-Aug       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.